2026-10-11T17:56:22Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33719365 2026-09-14T05:55:51Z category_388 portal_316 item_type_3 month_year_09_2026

Table 1_Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.docx Xiaohong Kang (9390038) Shiyan Zhang (1877710) Qiufeng Zhang (12038630) Zeqi Tang (23659420) Jiani Ji (16996867) Minyuan Ni (24087240) Li Wang (15202) Oncology and Carcinogenesis not elsewhere classified hepatocellular carcinoma meta-analysis PD-1/PD-L1 inhibitors prognosis targeted therapy transarterial chemoembolization Background<p>This study evaluated the efficacy of transarterial chemoembolization (TACE) combined with anti-vascular endothelial growth factor (VEGF)/tyrosine kinase inhibitors (TKIs) and programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitors in the treatment of unresectable hepatocellular carcinoma (uHCC).</p>Methods<p>Four databases were searched for studies evaluating the efficacy of TACE combined with anti-VEGF/TKIs and PD-1/PD-L1 inhibitors in uHCC. Pooled data were analyzed using random-effects models, with hazard ratio (HR) and 95% confidence intervals reported. Overall survival (OS) was the primary outcome, and progression-free survival (PFS) was a secondary outcome. Subgroup analyses were performed based on treatment regimens, therapy setting, and the sequencing of TACE and systemic therapy.</p>Results<p>A total of 53 studies (3 multicentre randomized controlled trials (RCTs) and 50 cohort studies) comprising over 10, 000 patients were included. Patients receiving triple therapy may derive greater OS (HR = 0.47, p<0.001) and PFS (HR = 0.52, p<0.001) benefits than those receiving other regimens. In OS subgroups, across various combinations, the TACE-bevacizumab-atezolizumab (HR = 0.44, p<0.001) and TACE-lenvatinib-tislelizumab regimens (HR = 0.44, p<0.001) appear to derive greater benefit. In contrast, the TACE-lenvatinib-pembrolizumab combination appears to show less benefit (HR = 0.67, p<0.001). Additionally, patients could potentially carry greater OS benefit with triple therapy, regardless of whether TACE was performed first (HR = 0.46, p<0.001) or systemic therapy was followed by TACE (HR = 0.42, p=0.001). Regarding treatment setting, the first-line group may obtain greater OS benefit (HR = 0.47, p<0.001), and the non-first-line group may also derive greater benefit (HR = 0.34, p=0.001).</p>Conclusion<p>Triple therapy (TACE with anti-VEGF/TKIs and PD-1/PD-L1 inhibitors) could significantly improve prognosis in uHCC, and its efficacy may vary depending on the treatment regimen, including the drug combination, treatment sequence, and lines.</p>Systematic Review Registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251151703, identifier CRD420251151703.</p> 2026-09-14T05:55:51Z Dataset Dataset 10.3389/fonc.2026.1927223.s005 https://figshare.com/articles/dataset/Table_1_Efficacy_of_PD-1_PD-L1_inhibitors_combined_with_anti-VEGF_TKIs_and_TACE_in_uHCC_a_meta-analysis_docx/33719365 CC BY 4.0